Filing Details
- Accession Number:
- 0000886163-22-000125
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2022-09-22 20:32:50
- Reporting Period:
- 2022-09-16
- Accepted Time:
- 2022-09-22 20:32:50
- Original Submission Date:
- 2022-09-16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1208906 | L John Higgins | 5980 Horton Street, Suite 405 Emeryville CA 94608 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-09-16 | 1,000 | $88.06 | 366,180 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- On September 16, 2022, due to an issue with the equity administration system of the company, the reporting person filed a Form 4 which inadvertently reported the sale of a higher number of shares than were actually sold by the reporting person. The correct number of shares sold is listed above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $88.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.